Third Quarter 2007 Financial Highlights:

     -- Total net revenues increased 57.3% over the third quarter 2006
to
        RMB56.1 million (US$7.5 million).
     -- Net revenue from our flagship recombinant human erythropoietin
        products, or EPO products, marketed under our EPIAO brand,
increased
        30.7% over the third quarter 2006 to RMB36.3 million (US$4.8
million).
     -- Net revenue from our protein-based therapeutic recombinant
human
        thrombopoietin products, or TPO products, marketed under our
TPIAO
        brand, increased 171.6% over the third quarter 2006 to RMB14.2
million
        (US$1.9 million).
     -- Operating income increased 61.5% over the third quarter 2006
to
        RMB17.1 million (US$2.3 million).
     -- Net income increased 151.4% over the third quarter 2006 to
RMB24.1
        million (US$3.2 million).
     -- Net income per ordinary share and net income per American
Depositary
        Share ("ADS") for the third quarter 2007 were RMB0.16 (US
$0.02) and
        RMB1.11 (US$0.15), respectively, compared to RMB0.10 and
RMB0.67,
        respectively, for the third quarter 2006.  Each ADS represents
seven
        ordinary shares.